FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/20/2026

1. TGT
2. EL
3. SPY
4. BILL
5. MRK
6. MRNA
7. ADI
8. LOW
9. WMT
10. TJX

Go back to FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Amgen Inc (NASDAQ: AMGN) Delayed: 432.46 -9.9 (2.24%)
Previous Close $442.36    52 Week High $176.85 
Open $435.78    52 Week Low $133.64 
Day High $441.34    P/E 65.13 
Day Low $431.46    EPS $6.64 
Volume 1,341,286